Aurinia Pharmaceuticals reported earnings of $ 0.23 per AUPH share on Oct 30, 2026, beating analysts' expectations by
| Report Date | Oct 30, 2026 |
|---|---|
| Forecasted EPS | $ 0.22 |
| Earnings Per Share (Surprise) | $ 0.23 (+$ 0.01) |
| Last Year's EPS | $ 0.2025 |
| EPS YoY Change |
Out of the last 100 earnings reporting periods, Aurinia Pharmaceuticals beat analysts’ expectations 35 times and fell short of expectations 28 time(s). Aurinia Pharmaceuticals reported earnings per share of $ 0.23 in the last report surpassing an estimated EPS of $ 0.22 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Oct 30, 2026 | $ 0.22 | $ 0.23 | $ 0.23 | |
| Aug 6, 2026 | $ 0.24 | $ 0.28 | $ 0.16 | |
| May 7, 2026 | $ 0.18 | $ 0.25 | $ 0.16 | |
| Feb 26, 2026 | $ 0.21 | $ 0.26 | $ 0.01 | |
| Nov 4, 2025 | $ 0.16 | $ 0.23 | $ 0.10 | |
| Jul 31, 2025 | $ 0.17 | $ 0.16 | $ 0.02 | |
| May 12, 2025 | $ 0.08 | $ 0.16 | -$ 0.03 | |
| Feb 27, 2025 | $ 0.03 | $ 0.01 | -$ 0.19 | |
| Nov 7, 2024 | $ 0.02 | $ 0.10 | -$ 0.09 | |
| Aug 1, 2024 | $ 0.01 | $ 0.02 | -$ 0.08 | |
| May 2, 2024 | -$ 0.14 | -$ 0.03 | -$ 0.18 | |
| Feb 15, 2024 | -$ 0.18 | -$ 0.19 | -$ 0.18 | |
| Nov 2, 2023 | -$ 0.17 | -$ 0.09 | -$ 0.06 | |
| Aug 3, 2023 | -$ 0.20 | -$ 0.08 | -$ 0.25 | |
| May 4, 2023 | -$ 0.24 | -$ 0.18 | -$ 0.27 | |
| Feb 28, 2023 | -$ 0.26 | -$ 0.18 | -$ 0.25 | |
| Nov 3, 2022 | -$ 0.18 | -$ 0.06 | -$ 0.39 | |
| Aug 4, 2022 | -$ 0.22 | -$ 0.25 | -$ 0.37 | |
| May 10, 2022 | -$ 0.26 | -$ 0.27 | -$ 0.40 | |
| Feb 28, 2022 | -$ 0.26 | -$ 0.25 | -$ 0.05 |
Aurinia Pharmaceuticals’s stock was trading at $ 17.21 on Oct 29, 2026 a day before the last earnings report was released.Following the release of the earnings report, AUPH’s price decreased to $ 16.14 on Oct 31, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Oct 30, 2026 | $ 0.23 | $ 17.21 | $ 16.14 | |
| Aug 6, 2026 | $ 0.28 | $ 15.19 | $ 15.85 | |
| May 7, 2026 | $ 0.25 | $ 16.25 | $ 15.23 | |
| Feb 26, 2026 | $ 0.26 | $ 14.43 | $ 14.17 | |
| Nov 4, 2025 | $ 0.23 | $ 13.17 | $ 14.45 | |
| Jul 31, 2025 | $ 0.16 | $ 9.05 | $ 10.49 | |
| May 12, 2025 | $ 0.16 | $ 8.00 | $ 7.82 | |
| Feb 27, 2025 | $ 0.01 | $ 7.95 | $ 7.95 | |
| Nov 7, 2024 | $ 0.10 | $ 7.52 | $ 8.32 | |
| Aug 1, 2024 | $ 0.02 | $ 5.88 | $ 5.50 | |
| May 2, 2024 | -$ 0.03 | $ 5.20 | $ 5.10 | |
| Feb 15, 2024 | -$ 0.19 | $ 7.97 | $ 5.85 | |
| Nov 2, 2023 | -$ 0.09 | $ 7.13 | $ 8.23 | |
| Aug 3, 2023 | -$ 0.08 | $ 10.13 | $ 9.82 | |
| May 4, 2023 | -$ 0.18 | $ 11.69 | $ 11.56 | |
| Feb 28, 2023 | -$ 0.18 | $ 8.33 | $ 8.99 | |
| Nov 3, 2022 | -$ 0.06 | $ 7.61 | $ 5.15 | |
| Aug 4, 2022 | -$ 0.25 | $ 8.50 | $ 8.37 | |
| May 10, 2022 | -$ 0.27 | $ 8.95 | $ 9.58 | |
| Feb 28, 2022 | -$ 0.25 | $ 16.24 | $ 12.01 |
Aurinia Pharmaceuticals released its most recent earnings reports in October 2026, August 2026, May 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Aurinia Pharmaceuticals beat analysts’ expectations during the last earnings period by
